Table 2.
Primary site Exp SIR 95% CI | Obs | Exp | SIR | 95% CI |
---|---|---|---|---|
All sites | 408 | 395.8 | 1.03 | 0.93 to 1.13 |
Mouth, pharynx | 12 | 10.3 | 1.16 | 0.60 to 2.03 |
Oesophagus | 4 | 4.6 | 0.86 | 0.24 to 2.20 |
Stomach | 12 | 14.9 | 0.80 | 0.42 to 1.40 |
Colon | 22 | 16.8 | 1.30 | 0.82 to 1.97 |
Rectum | 14 | 13.3 | 1.06 | 0.58 to 1.77 |
Liver | 4 | 5.2 | 0.78 | 0.21 to 1.98 |
Gallbladder | 4 | 2.5 | 1.58 | 0.43 to 4.03 |
Pancreas | 16 | 13.1 | 1.22 | 0.70 to 1.98 |
Nose, sinuses | 2 | 1.0 | 2.05 | 0.25 to 7.42 |
Larynx | 4 | 3.4 | 1.19 | 0.33 to 3.05 |
Lung, bronchus | 37 | 47.0 | 0.79 | 0.55 to 1.08 |
Breast | 31 | 30.8 | 1.01 | 0.68 to 1.42 |
Cervix uteri | 20 | 16.7 | 1.20 | 0.73 to 1.85 |
Corpus uteri | 7 | 4.5 | 1.54 | 0.62 to 3.18 |
Ovary | 2 | 4.0 | 0.50 | 0.06 to 1.81 |
Prostate | 89 | 67.8 | 1.31 | 1.05 to 1.61* |
Testis | 5 | 6.4 | 0.78 | 0.25 to 1.83 |
Kidney | 6 | 15.8 | 0.38 | 0.14 to 0.82** |
Bladder | 14 | 14.0 | 1.00 | 0.55 to 1.67 |
Skin melanoma | 24 | 16.7 | 1.44 | 0.92 to 2.14 |
Other skin | 5 | 7.6 | 0.66 | 0.21 to 1.53 |
Brain/nervous system | 18 | 19.3 | 0.93 | 0.55 to 1.47 |
Thyroid | 10 | 13.7 | 0.73 | 0.35 to 1.34 |
Soft tissue | 3 | 3.7 | 0.82 | 0.17 to 2.40 |
Hodgkin lymphoma | 3 | 5.8 | 0.52 | 0.11 to 1.50 |
Non-Hodgkin lymphoma | 24 | 19.1 | 1.26 | 0.81 to 1.87 |
Multiple myeloma | 6 | 4.6 | 1.32 | 0.48 to 2.86 |
Leukaemia | 15 | 11.5 | 1.31 | 0.73 to 2.15 |
Not included above: skin, basal cell carcinoma | 88 | 70.3 | 1.25 | 1.00 to 1.54* |
Included are sites with Exp>2, and nasal cancer because of a priori interest.
*p<0.05.
**p<0.01.